首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HGF |
| Uniprot No | P14210 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-728aa |
| 氨基酸序列 | QRKRRNTIHE FKKSAKTTLI KIDPALKIKT KKVNTADQCA NRCTRNKGLP FTCKAFVFDK ARKQCLWFPF NSMSSGVKKE FGHEFDLYEN KDYIRNCIIG KGRSYKGTVS ITKSGIKCQP WSSMIPHEHS FLPSSYRGKD LQENYCRNPR GEEGGPWCFT SNPEVRYEVC DIPQCSEVEC MTCNGESYRG LMDHTESGKI CQRWDHQTPH RHKFLPERYP DKGFDDNYCR NPDGQPRPWC YTLDPHTRWE YCAIKTCADN TMNDTDVPLE TTECIQGQGE GYRGTVNTIW NGIPCQRWDS QYPHEHDMTP ENFKCKDLRE NYCRNPDGSE SPWCFTTDPN IRVGYCSQIP NCDMSHGQDC YRGNGKNYMG NLSQTRSGLT CSMWDKNMED LHRHIFWEPD ASKLNENYCR NPDDDAHGPW CYTGNPLIPW DYCPISRCEG DTTPTIVNLD HPVISCAKTK QLRVVNGIPT RTNIGWMVSL RYRNKHICGG SLIKESWVLT ARQCFPSRDL KDYEAWLGIH DVHGRGDEKC KQVLNVSQLV YGPEGSDLVL MKLARPAVLD DFVSTIDLPN YGCTIPEKTS CSVYGWGYTG LINYDGLLRV AHLYIMGNEK CSQHHRGKVT LNESEICAGA EKIGSGPCEG DYGGPLVCEQ HKMRMVLGVI VPGRGCAIPN RPGIFVRVAY YAKWIHKIIL TYKVPQS |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Molecular cloning and expression of human hepatocyte growth factor"**
*作者：Nakamura T, et al.*
摘要：该研究首次报道了人HGF重组蛋白的cDNA克隆及体外表达，证实其具有刺激肝细胞增殖和迁移的生物活性，为后续治疗应用奠定基础。
2. **"Hepatocyte growth factor: renotropic role and potential therapeutics for kidney diseases"**
*作者：Matsumoto K, Nakamura T*
摘要：综述HGF重组蛋白在肾脏修复中的作用，强调其通过抗纤维化和促细胞再生机制治疗急性肾损伤及慢性肾病的前景。
3. **"Structure and function of hepatocyte growth factor/scatter factor"**
*作者：Zarnegar R, et al.*
摘要：解析HGF重组蛋白的分子结构，阐明其与c-Met受体结合机制，揭示其在组织形态发生和肿瘤侵袭中的双重功能。
4. **"Recombinant HGF suppresses metastatic liver cancer by inhibiting EMT in preclinical models"**
*作者：Jiang WG, et al.*
摘要：实验证明局部注射HGF重组蛋白可通过逆转上皮-间质转化(EMT)抑制肝癌转移，为抗肿瘤治疗提供新策略。
**Background of HGF Recombinant Protein**
Hepatocyte Growth Factor (HGF), also known as scatter factor, is a pleiotropic cytokine first identified in the 1980s for its ability to stimulate hepatocyte proliferation. It is primarily produced by mesenchymal cells and acts on epithelial and endothelial cells via the c-Met receptor, a tyrosine kinase transmembrane protein. HGF plays critical roles in embryonic development, organ regeneration, wound healing, and angiogenesis. Structurally, mature HGF is a heterodimer composed of a 69 kDa α-chain and a 34 kDa β-chain linked by disulfide bonds. The α-chain contains an N-terminal hairpin loop and four kringle domains, while the β-chain resembles serine protease enzymes, though it lacks enzymatic activity.
Recombinant HGF (rHGF) is engineered using biotechnological methods, such as expression in bacterial, yeast, or mammalian cell systems, to ensure proper folding and post-translational modifications. This allows large-scale production of bioactive HGF for research and therapeutic applications. rHGF retains the natural protein’s ability to activate c-Met signaling, triggering downstream pathways like MAPK/ERK, PI3K/Akt, and STAT, which regulate cell proliferation, migration, survival, and morphogenesis.
Clinically, rHGF has shown potential in treating liver fibrosis, acute kidney injury, and cardiovascular diseases by promoting tissue repair. It is also explored in regenerative medicine to enhance stem cell differentiation and tissue engineering. However, its dual role in both tissue regeneration and cancer progression (via c-Met activation in tumors) necessitates careful therapeutic evaluation. Current research focuses on optimizing delivery systems and understanding context-dependent mechanisms to harness its regenerative benefits while mitigating oncogenic risks.
In summary, rHGF is a versatile tool bridging developmental biology, disease mechanisms, and translational medicine, offering hope for conditions with unmet therapeutic needs.
×
